I like your numbers but $100m revenue won't be achieved in 1-2 years IMO.
To reach that will take some time but if revenues increase substantially each quarter, the market will take notice and revalue this accordingly.
If they can get to $10-$20m revenue for 2017, they will be doing well IMO.
Take a look at Pharmaxis with its EMA approval for Bronchitol. Revenues aren't impressive.
Obv FDA approval will be huge if Clinuvel are successful in Europe.
- Forums
- ASX - By Stock
- CUV
- Ann: SCENESSE Treatment in Europe-CUV.AX
Ann: SCENESSE Treatment in Europe-CUV.AX, page-4
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
|
|||||
Last
$14.80 |
Change
0.220(1.51%) |
Mkt cap ! $741.1M |
Open | High | Low | Value | Volume |
$14.61 | $14.99 | $14.40 | $820.9K | 56.14K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 1069 | $14.79 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.81 | 247 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 153 | 14.790 |
3 | 232 | 14.780 |
3 | 199 | 14.770 |
4 | 228 | 14.760 |
3 | 214 | 14.750 |
Price($) | Vol. | No. |
---|---|---|
14.810 | 294 | 7 |
14.820 | 390 | 2 |
14.830 | 217 | 5 |
14.840 | 1794 | 8 |
14.850 | 3989 | 6 |
Last trade - 13.55pm 10/07/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online